Gadofosveset

Drug Profile

Gadofosveset

Alternative Names: Ablavar; AngioMARK; Gadofosveset-trisodium; MS 325; MS 32520; Vasovist; ZK 236018

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator Massachusetts General Hospital
  • Developer EPIX Pharmaceuticals
  • Class Lanthanoid series elements; Organometallic compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 20 Nov 2009 The CHMP of the European Medicines Agency makes recommendations to minimise the risk of nephrogenic systemic fibrosis
  • 08 Oct 2009 Adverse events data from post-marketing review released by Lantheus Medical Imaging
  • 07 Apr 2009 Gadofosveset out-licensed to Lanthus Medical Imaging in the US, Puerto Rico, Canada and Australia ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top